Company overview
SphingoTec GmbH develops and markets proprietary blood-based biomarkers for diagnosing, predicting, and monitoring acute conditions like acute kidney injury, sepsis, and acute heart failure. Their offerings include chemiluminescence microtiter plate assays for biomarkers such as penKid (Proenkephalin A 119-159) and bio-ADM (bioactive Adrenomedullin 1-52), designed for research and high-throughput laboratory use. They partner with companies like Beckman Coulter to enable automated assays on immunoassay analyzers for broader clinical adoption.
SphingoTec GmbH is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include sphingotec, penkid biomarker, bio-adm assay, acute kidney injury, critical care diagnostics, sepsis biomarkers.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with SphingoTec GmbH include Assay, Diagnostic — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.sphingotec.eu
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- sphingotec, penkid biomarker, bio-adm assay, acute kidney injury, critical care diagnostics, sepsis biomarkers
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What biomarkers does SphingoTec offer?
- SphingoTec offers proprietary biomarkers including penKid for real-time kidney function assessment in acute kidney injury and bio-ADM for sepsis and hemodynamic stress monitoring.
- What assay formats are available from SphingoTec?
- They provide chemiluminescence sandwich immunoassay-based microtiter plate assays for research use, with partnerships enabling automated high-throughput assays on platforms like Beckman Coulter's Access Family analyzers.
- What are SphingoTec's key partnerships and regulatory status?
- SphingoTec has partnered with Beckman Coulter for penKid assays on IVD-certified platforms implemented in university hospitals; their assays support critical care diagnostics with high sensitivity and no high-dose hook effect.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
